Statin use after renal transplantation: A systematic quality review of trial-based evidence

Nephrology Dialysis Transplantation

Volumn 19, Issue 9, 2004, Pages 2378-2386

  Lentine, Krista L ^a,b   Brennan, Daniel C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HMG CoA reductase inhibitors; Kidney transplantation; Quality evaluation; Randomized clinical trials; Statins

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; CERIVASTATIN; CYCLOSPORIN A; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PRAVASTATIN; SIMVASTATIN; STEROID;

ACUTE GRAFT REJECTION; ANALYSIS OF VARIANCE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; EVIDENCE BASED MEDICINE; HEPATITIS; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MYALGIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK REDUCTION; SCORING SYSTEM;

CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS;

EID: 4544239717     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh385     Document Type: Article

References (28)

1. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9: 2135-2141
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
3. UNOS. UNOS-SRTR 2000
4. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc 1997; 278: 313-321
5. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627
6. Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271-1278
7. Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 2002; 40: 638-643
8. National Institutes of Health DoRG, Research Analysis and Evaluation Branch. NIH Inventory of Clinical Trials: Fiscal Year 1979, Vol. 1; 1979
9. Katznelson S, Wilkinson AH, Kobashigawa JA et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation 1996; 61: 1469-1474
10. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc 2000; 32: 622-625
11. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72: 223-227
12. Holdaas H, Jardine AG, Wheeler DC et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001; 60: 1990-1997
13. Sahu K, Sharma R, Gupta A et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant 2001; 15: 173-175
14. Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant 1993; 8: 637-641
15. Arnadottir M, Eriksson LO, Germershausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in cyclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 68: 57-62
16. Renders L, Mayer-Kadner I, Koch C et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001; 16: 141-146
17. Santos AF, Keitel E, Bittar AE et al. Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. Transplant Proc 2001; 33: 1194-1195
18. Hausberg M, Kosch M, Stam F et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 2001; 59: 1473-1479
19. Cofan F, Gilabert R, Zambon D et al. Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. Transplant Proc 2002; 34: 384-388
20. Asberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transplant 2003; 17: 385-390
21. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multi-centre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031
22. Balas EA, Austin SM, Ewigman BG, Brown GD, Mitchell JA. Methods of randomized controlled clinical trials in health services research. Med Care 1995; 33: 687-699
23. Justice AC, Cho MK, Winker MA, Berlin JA, Rennie D. Does masking author identity improve peer review quality? A randomized controlled trial. PEER Investigators. J Am Med Assoc 1998; 280: 240-242
24. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587
25. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504
26. Kasiske B, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4 [Suppl 7]: 13-53
27. Jampel HD, Friedman DS, Lubomski LH et al. Methodologic rigor of clinical trials on surgical management of eyes with coexisting cataract and glaucoma. Ophthalmology 2002; 109: 1892-1901
28. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996; 12: 195-208